Administer orally, with or without food. Swallow the tablet whole with a glass of water. Do not crush, chew, or break the tablet.

Relaxium enhances the effect of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain, by binding to specific GABA-A receptors. This increases chloride ion influx, leading to hyperpolarization and stabilization of neuronal membranes, resulting in reduced neuronal excitability and a calming effect.

• •Hypersensitivity to Relaxium or any excipients
• •Acute narrow-angle glaucoma
• •Severe respiratory insufficiency
• •Sleep apnea syndrome
• •Severe hepatic impairment
• •Myasthenia gravis

Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.

Symptoms of overdose typically include somnolence, confusion, diminished reflexes, impaired coordination, and coma. In severe cases, respiratory depression and hypotension may occur. Management involves general supportive measures, maintaining a patent airway, gastric lavage, and intravenous fluids. Flumazenil, a benzodiazepine receptor antagonist, may be considered in severe cases, but caution is advised due to the risk of inducing seizures.

Pregnancy Category D. Relaxium should not be used during pregnancy, especially during the first trimester, due to potential for fetal harm, including congenital malformations and withdrawal symptoms in neonates. It is excreted in breast milk; therefore, use during lactation is contraindicated due to potential for sedation, poor feeding, and weight loss in infants.